TrialDiabetes, obesity & metabolism2025

Effects of combined treatment with zibotentan and dapagliflozin compared to dapagliflozin alone in patients with diabetic and non-diabetic chronic kidney disease.

Victor Wasehuus et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.